Chemotherapy Is of limited efficacy in the control of contralateral testicular intraepithelial neoplasia in patients with testicular germ cell cancer

Oncology

Volumn 77, Issue 1, 2009, Pages 33-39

  Kleinschmidt, Klaus ^a   Dieckmann, Klaus Peter ^b   Georgiew, Alexander ^c   Loy, Volker ^d   Weissbach, Lothar ^e  

^a DR HORST SCHMIDT KLINIKEN   (Germany)

^b ALBERTINEN KRANKENHAUS   (Germany)

^c Departments of Urology

^d VIVANTES KLINIKUM AM URBAN   (Germany)

^e Euromed Clinic   (Germany)

Author keywords

Carboplatin; Chemotherapy; Cisplatin; Testicular germ cell neoplasm; Testicular intraepithelial neoplasia

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CISPLATIN; ETOPOSIDE; ANTINEOPLASTIC AGENT;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CARCINOMA IN SITU; CLINICAL ARTICLE; GERM CELL TUMOR; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MULTIPLE CYCLE TREATMENT; NON SEMINOMATOUS GERMINOMA; ORCHIECTOMY; PRIORITY JOURNAL; SEMINOMA; SPERMATOGENESIS; TESTIS BIOPSY; TREATMENT FAILURE; CANCER STAGING; MULTIMODALITY CANCER THERAPY; PROGNOSIS; RADIATION DOSE; TESTIS TUMOR; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CARBOPLATIN; CARCINOMA IN SITU; COMBINED MODALITY THERAPY; ETOPOSIDE; HUMANS; MALE; NEOPLASM STAGING; ORCHIECTOMY; PROGNOSIS; RADIOTHERAPY DOSAGE; SEMINOMA; TESTICULAR NEOPLASMS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 65549092884     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000218202     Document Type: Article

References (34)

1. Oosterhuis JW, Looijenga LH: Testicular germ-cell tumours in a broader perspective. Nat Rev Cancer 2005;5:210-222.
2. Dieckmann KP, Skakkebaek NE: Carcinoma in situ of the testis: a review of biological and clinical features. Int J Cancer 1999;83:815-822.
3. Kleinschmidt K, Kemper J, Holstein AF: Carcinoma in situ of the testis in the presence of contralateral germ cell tumor. Eur Urol 1989;16:74-77.
4. Skakkebaek NE, Berthelsen JG, Giwercman A, Müller J: Carcinoma in situ of the testis: possible origin from gonocytes and precursor of all types of germ cell tumours except spermatocytoma. Int J Androl 1987;10:19-28.
5. Winstanley AM, Mikuz G, Debruyne F, Schulman CC, Parkinson MC: Handling and reporting of biopsy and surgical specimens of testicular cancer. Eur Urol 2004;45:564-573.
6. Looijenga LH, Stoop H, de Leeuw HP, et al: POU5F1 (OCT3/4) identifies cells with plu-ripotent potential in human germ cell tumors. Cancer Res 2003;63:2244-2250.
7. Hoei-Hansen CE, Rajpert-De Meyts E, Daugaard G, Skakkebaek NE: Carcinoma in situ testis, the progenitor of testicular germ cell tumours: a clinical review. Ann Oncol 2005;16:863-868.
8. Classen J, Dieckmann KP, Bamberg M, et al: Radiotherapy with 16 Gy may fail to eradicate testicular intraepithelial neoplasia: preliminary communication of a dose-reduction trial of the German Testicular Cancer Study Group. Br J Cancer 2003;88:828-831.
9. Giwercman A, von der Maase H, Berthelsen JG, Rorth M, Bertelsen A, Skakkebaek NE: Localized irradiation of testes with carcinoma in situ: effects on Leydig cell function and eradication of malignant germ cells in 20 patients. J Clin Endocrinol Metab 1991;73:596-603.
10. Dieckmann K P, Loy V: The value of the biopsy of the contralateral testis in patients with testicular germ cell cancer: the recent German experience. APMIS 1998;106:13-20.
11. Christensen TB, Daugaard G, Geertsen PF, von der Maase H: Effect of chemotherapy on carcinoma in situ of the testis. Ann Oncol 1998;9:657-660.
12. Dieckmann K P, Kulejewski M, Pichlmeier U, Loy V: Diagnosis of contralateral testicular intraepithelial neoplasia (TIN) in patients with testicular germ cell cancer: systematic two-site biopsies are more sensitive than a single random biopsy. Eur Urol 2007;51:175-185.
13. Mumperow E, Lauke H, Holstein AF, Hartmann M: Further practical experiences in the recognition and management of carcinoma in situ of the testis. Urol int 1992;48:162-166.
14. Bottomley D, Fisher C, Hendry WF, Horwich A: Persistent carcinoma in situ of the testis after chemotherapy for advanced testicular germ cell tumours. Br J Urol 1990;66:420-424.
15. Ramani VA, Grey BR, Addla SK, Dunham MP, Sangar VK, Clarke NW: Histological outcome of delayed orchidectomy after primary chemotherapy for metastatic germ cell tumour of the testis. Clin Oncol (R Coll Ra-diol) 2008;20:247-252.
16. Dieckmann KP, Loy V: Intratesticular effects of cisplatin-based chemotherapy. Eur Urol 19 95;28:25-30.
17. Fossa SD, Chen J, Schonfeld SJ, et al: Risk of contralateral testicular cancer: a populationbased study of 29,515 US men. J Natl Cancer Inst 2005;97:1056-1066.
18. Pamenter B, De Bono JS, Brown IL, et al: Bilateral testicular cancer: a preventable problem? Experience from a large cancer centre. BJU Int 2003;92:43-46.
19. Theodore C, Terrier-Lacombe MJ, Laplanche A, et al: Bilateral germ-cell tumours: 22-year experience at the Institut Gustave Roussy. Br J Cancer 2004;90:55-59.
20. Scholz M, Zehender M, Thalmann GN, Borner M, Thoni H, Studer UE: Extragonadal retroperitoneal germ cell tumor: evidence of origin in the testis. Ann Oncol 2002;13:121-124.
21. Fossa SD, Aass N, Heilo A, et al: Testicular carcinoma in situ in patients with extragonadal germ-cell tumours: the clinical role of pretreatment biopsy. Ann Oncol 20 03;14:1412 -1418.
22. Hartmann JT, Fossa SD, Nichols CR, et al: Incidence of metachronous testicular cancer in patients with extragonadal germ cell tumors. J Natl Cancer Inst 2001;93:1733-1738.
23. Bokemeyer C, Schmoll HJ, Schöffski P, Harstrick A, Bading M, Poliwoda H: Bilateral testicular tumours: prevalence and clinical implications. Eur J Cancer 1993;29A:874-876.
24. Park DS, Prow DM, Amato RJ, Ro JY, Logothetis CJ: Clinical characteristics of metachronous bilateral testicular tumors in the chemotherapeutic era. Yonsei Med J 1999;40:137-143.
25. Oliver RT, Mason MD, Mead GM, et al: Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised tria l. Lancet 2005;366:293-300.
26. Dieckmann KP, Boeckmann W, Brosig W, Jonas D, Bauer HW: Bilateral testicular germ cell tumors. Report of nine cases and review of the literature. Cancer 1986;57:1254-1258.
27. Powles T, Robinson D, Shamash J, Moller H, Tranter N, Oliver T: The long-term risks of adjuvant carboplatin treatment for stage I seminoma of the testis. Ann Oncol 2008;19:443-447.
28. Petersen PM, Giwercman A, Daugaard G, et al: Effect of graded testicular doses of radiotherapy in patients treated for carcinoma-insitu in the testis. J Clin Oncol 2002;20:1537-1543.
29. Albers P: Management of stage I testis cancer. Eur Urol 2007;51:34-44.
30. Weissbach L: Organ preserving surgery of malignant germ cell tumors. J Urol 1995;153:90-93.
31. Heidenreich A, Weissbach L, Höltl W, et al: Organ sparing surgery for malignant germ cell tumors of the testis. J Urol 2001;166:2161-2165.
32. Krege S, Beyer J, Souchon R, et al: European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I. Eur Urol 20 08;53:478-496.
33. Souchon R, Gertenbach U, Dieckmann KP, et al: Contralateral testicular cancer in spite of TIN-negative double biopsies and interval cisplatin chemotherapy. Strahlenther Onkol 2006;182:289-292.
34. Kliesch S, Thomaidis T, Schütte B, et al: Update on the diagnostic safety for detection of testicular intraepithelial neoplasia (TIN). APMIS 20 03;111:70 -74.